BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Alas M, Saghaeidehkordi A, Kaur K. Peptide-Drug Conjugates with Different Linkers for Cancer Therapy. J Med Chem 2021;64:216-32. [PMID: 33382619 DOI: 10.1021/acs.jmedchem.0c01530] [Cited by in Crossref: 35] [Cited by in F6Publishing: 41] [Article Influence: 17.5] [Reference Citation Analysis]
Number Citing Articles
1 Yang Y, Wang S, Ma P, Jiang Y, Cheng K, Yu Y, Jiang N, Miao H, Tang Q, Liu F, Zha Y, Li N. Drug conjugate-based anticancer therapy - Current status and perspectives. Cancer Letters 2023;552:215969. [DOI: 10.1016/j.canlet.2022.215969] [Reference Citation Analysis]
2 Hou L, Hou Y, Liang Y, Chen B, Zhang X, Wang Y, Zhou K, Zhong T, Long B, Pang W, Wang L, Han X, Li L, Xu C, Gross I, Gaiddon C, Fu W, Yao H, Meng X. Anti-tumor effects of P-LPK-CPT, a peptide-camptothecin conjugate, in colorectal cancer. Commun Biol 2022;5:1248. [DOI: 10.1038/s42003-022-04191-1] [Reference Citation Analysis]
3 Wu M, Huang W, Yang N, Liu Y. Learn from antibody–drug conjugates: consideration in the future construction of peptide-drug conjugates for cancer therapy. Exp Hematol Oncol 2022;11:93. [DOI: 10.1186/s40164-022-00347-1] [Reference Citation Analysis]
4 Godara P, Naik B, Meghwal R, Ojha R, Srivastava V, Prajapati VK, Prusty D. Rational designing of peptide-ligand conjugates-based immunotherapy for the treatment of complicated malaria. Life Sciences 2022. [DOI: 10.1016/j.lfs.2022.121121] [Reference Citation Analysis]
5 Yu X, Wang H, Liu X, Huang L, Song N, Song Y, Mo X, Lou S, Shi L, Yu Z. Assembling synergistic peptide-drug conjugates for dual-targeted treatment of cancer metastasis. Nano Today 2022;46:101594. [DOI: 10.1016/j.nantod.2022.101594] [Reference Citation Analysis]
6 Li C, Li Y, Li G, Wu S. Functional Nanoparticles for Enhanced Cancer Therapy. Pharmaceutics 2022;14:1682. [PMID: 36015307 DOI: 10.3390/pharmaceutics14081682] [Reference Citation Analysis]
7 Fu C, Yu L, Miao Y, Liu X, Yu Z, Wei M. Peptide‒drug conjugates (PDCs): A novel trend of research and development on targeted therapy, hype or hope? Acta Pharmaceutica Sinica B 2022. [DOI: 10.1016/j.apsb.2022.07.020] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Das M, Joshi A, Devkar R, Seshadri S, Thakore S. Tumor homing dextran and curcumin derived amphiphilic functional polymer self-assembling to tubustecan nanoarchitectures: A strategy of adorning the golden spice (curcumin) for taming the red devil (Dox). Journal of Drug Delivery Science and Technology 2022. [DOI: 10.1016/j.jddst.2022.103666] [Reference Citation Analysis]
9 Nteli P, Bajwa DE, Politakis D, Michalopoulos C, Kefala-Narin A, Efstathopoulos EP, Gazouli M. Nanomedicine approaches for treatment of hematologic and oncologic malignancies. World J Clin Oncol 2022; 13(7): 553-566 [DOI: 10.5306/wjco.v13.i7.553] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Liang J, Guo R, Xuan M, Sun Q, Wu W. An Acid-Sensitive Nanofiber Conjugate Based on a Short Aromatic Peptide for Targeted Delivery of Doxorubicin in Liver Cancer. IJN 2022;Volume 17:2961-73. [DOI: 10.2147/ijn.s359642] [Reference Citation Analysis]
11 Yang S, Banik N, Han B, Lee D, Park J. Peptide-Based Bioconjugates and Therapeutics for Targeted Anticancer Therapy. Pharmaceutics 2022;14:1378. [DOI: 10.3390/pharmaceutics14071378] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Bell HJ, Malins LR. Peptide macrocyclisation via late-stage reductive amination. Org Biomol Chem 2022. [PMID: 35621075 DOI: 10.1039/d2ob00782g] [Reference Citation Analysis]
13 Sun SL, Wu SH, Kang JB, Ma YY, Chen L, Cao P, Chang L, Ding N, Xue X, Li NG, Shi ZH. Medicinal Chemistry Strategies for the Development of Bruton's Tyrosine Kinase Inhibitors against Resistance. J Med Chem 2022. [PMID: 35594541 DOI: 10.1021/acs.jmedchem.2c00030] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
14 Tong S, Darwish S, Ariani HHN, Lozada KA, Salehi D, Cinelli MA, Silverman RB, Kaur K, Yang S. A Small Peptide Increases Drug Delivery in Human Melanoma Cells. Pharmaceutics 2022;14:1036. [DOI: 10.3390/pharmaceutics14051036] [Reference Citation Analysis]
15 Sun Y. A Sequential Stimulus-Responsive Nanoparticle Platform for Enhanced Tumor Growth Inhibition and Efficient Drug Delivery. J Pharm Innov. [DOI: 10.1007/s12247-022-09653-x] [Reference Citation Analysis]
16 Li X, Wang Y, Feng C, Chen H, Gao Y. Chemical Modification of Chitosan for Developing Cancer Nanotheranostics. Biomacromolecules 2022. [PMID: 35522524 DOI: 10.1021/acs.biomac.2c00184] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
17 Carl SM, Herrera‐ruiz D, Bhardwaj RK, Gudmundsson O, Mowery S, Knipp GT. MAMMALIAN OLIGOPEPTIDE TRANSPORTERS. Drug Transporters 2022. [DOI: 10.1002/9781119739883.ch6] [Reference Citation Analysis]
18 Wang Y, Xie F, Liu L, Xu X, Fan S, Zhong W, Zhou X. Development of applicable thiol-linked antibody-drug conjugates with improved stability and therapeutic index. Drug Deliv 2022;29:754-66. [PMID: 35244495 DOI: 10.1080/10717544.2022.2039807] [Reference Citation Analysis]
19 Zhang T, Ouyang X, Gou S, Zhang Y, Yan N, Chang L, Li B, Zhang F, Liu H, Ni J. Novel Synovial Targeting Peptide-Sinomenine Conjugates as a Potential Strategy for the Treatment of Rheumatoid Arthritis. Int J Pharm 2022;:121628. [PMID: 35245636 DOI: 10.1016/j.ijpharm.2022.121628] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
20 Shang Q, Su Y, Leslie F, Sun M, Wang F. Advances in peptide drug conjugate-based supramolecular hydrogel systems for local drug delivery. Medicine in Drug Discovery 2022. [DOI: 10.1016/j.medidd.2022.100125] [Reference Citation Analysis]
21 Wang L, Chen H, Wang F, Zhang X. The development of peptide-drug conjugates (PDCs) strategies for paclitaxel. Expert Opin Drug Deliv 2022. [PMID: 35130795 DOI: 10.1080/17425247.2022.2039621] [Reference Citation Analysis]
22 Xu J, Li X, Du Y. Antibody-Pattern Recognition Receptor Agonist Conjugates: A Promising Therapeutic Strategy for Cancer. Adv Biol (Weinh) 2022;:e2101065. [PMID: 35122418 DOI: 10.1002/adbi.202101065] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
23 Ramamurthi D, Selvaraj J, Patnaik SK, Palathoti N, Rajeshkumar R, Chandrasekar MJN. Synthesis and Characterization of Dipeptide–Drug Conjugate: The Use of Linker Coupling Reaction. Int J Pept Res Ther 2022;28. [DOI: 10.1007/s10989-022-10363-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Zoghebi K, Aliabadi HM, Tiwari RK, Parang K. [(WR)8WKβA]-Doxorubicin Conjugate: A Delivery System to Overcome Multi-Drug Resistance against Doxorubicin. Cells 2022;11:301. [DOI: 10.3390/cells11020301] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
25 Garg P. Radiobioconjugate targeted therapy in cancer, using radiolabeled mediated biological analogs: Desired qualities and selective targeting approach. Biomed Biotechnol Res J 2022;6:40. [DOI: 10.4103/bbrj.bbrj_282_21] [Reference Citation Analysis]
26 Cheng Y, Kong F. Low molecular weight protamine-corticosteroid conjugate for topical treatment of psoriasis: A hypothesis. Medical Hypotheses 2022. [DOI: 10.1016/j.mehy.2022.110776] [Reference Citation Analysis]
27 Wang D, Tian Y, Zhang Y, Sun X, Wu Y, Liu R, Zeng F, Du J, Hu K. An assembly-inducing PDC enabling the efficient nuclear delivery of nucleic acid for cancer stem-like cell suppression. Nanoscale 2022;14:15384-15392. [DOI: 10.1039/d2nr02118h] [Reference Citation Analysis]
28 Ogunnigbagbe O, Bunick CG, Kaur K. Keratin 1 as a cell-surface receptor in cancer. Biochim Biophys Acta Rev Cancer 2021;1877:188664. [PMID: 34890750 DOI: 10.1016/j.bbcan.2021.188664] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
29 Lian H, Guan P, Tan H, Zhang X, Meng Z. Near-infrared light triggered multi-hit therapeutic nanosystem for tumor specific photothermal effect amplified signal pathway regulation and ferroptosis. Bioact Mater 2022;9:63-76. [PMID: 34820556 DOI: 10.1016/j.bioactmat.2021.07.014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
30 Wang MD, Hou DY, Lv GT, Li RX, Hu XJ, Wang ZJ, Zhang NY, Yi L, Xu WH, Wang H. Targeted in situ self-assembly augments peptide drug conjugate cell-entry efficiency. Biomaterials 2021;278:121139. [PMID: 34624753 DOI: 10.1016/j.biomaterials.2021.121139] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 12.0] [Reference Citation Analysis]
31 Shoari A, Tooyserkani R, Tahmasebi M, Löwik DWPM. Delivery of Various Cargos into Cancer Cells and Tissues via Cell-Penetrating Peptides: A Review of the Last Decade. Pharmaceutics 2021;13:1391. [PMID: 34575464 DOI: 10.3390/pharmaceutics13091391] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
32 Antony P, Vijayan R. Bioactive Peptides as Potential Nutraceuticals for Diabetes Therapy: A Comprehensive Review. Int J Mol Sci 2021;22:9059. [PMID: 34445765 DOI: 10.3390/ijms22169059] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
33 Zhang J, Wang M, Wang H, Xu H, Chen J, Guo Z, Ma B, Ban SR, Dai HX. Construction of 2-alkynyl aza-spiro[4,5]indole scaffolds via sequential C-H activations for modular click chemistry libraries. Chem Commun (Camb) 2021;57:8656-9. [PMID: 34373875 DOI: 10.1039/d1cc02798k] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
34 Zhu YS, Tang K, Lv J. Peptide-drug conjugate-based novel molecular drug delivery system in cancer. Trends Pharmacol Sci 2021:S0165-6147(21)00136-X. [PMID: 34334251 DOI: 10.1016/j.tips.2021.07.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 11.0] [Reference Citation Analysis]
35 Park SE, El-Sayed NS, Shamloo K, Lohan S, Kumar S, Sajid MI, Tiwari RK. Targeted Delivery of Cabazitaxel Using Cyclic Cell-Penetrating Peptide and Biomarkers of Extracellular Matrix for Prostate and Breast Cancer Therapy. Bioconjug Chem 2021. [PMID: 34309357 DOI: 10.1021/acs.bioconjchem.1c00319] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
36 Zhou J, Li Y, Huang W, Shi W, Qian H. Source and exploration of the peptides used to construct peptide-drug conjugates. Eur J Med Chem 2021;224:113712. [PMID: 34303870 DOI: 10.1016/j.ejmech.2021.113712] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
37 Battistini L, Bugatti K, Sartori A, Curti C, Zanardi F. RGD Peptide‐Drug Conjugates as Effective Dual Targeting Platforms: Recent Advances. Eur J Org Chem 2021;2021:2506-28. [DOI: 10.1002/ejoc.202100240] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
38 Saghaeidehkordi A, Chen S, Yang S, Kaur K. Evaluation of a Keratin 1 Targeting Peptide-Doxorubicin Conjugate in a Mouse Model of Triple-Negative Breast Cancer. Pharmaceutics 2021;13:661. [PMID: 34063098 DOI: 10.3390/pharmaceutics13050661] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
39 Knerr L, Prakash TP, Lee R, Drury Iii WJ, Nikan M, Fu W, Pirie E, Maria LD, Valeur E, Hayen A, Ölwegård-halvarsson M, Broddefalk J, Ämmälä C, Østergaard ME, Meuller J, Sundström L, Andersson P, Janzén D, Jansson-löfmark R, Seth PP, Andersson S. Glucagon Like Peptide 1 Receptor Agonists for Targeted Delivery of Antisense Oligonucleotides to Pancreatic Beta Cell. J Am Chem Soc 2021;143:3416-29. [DOI: 10.1021/jacs.0c12043] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]